Polyganics Initiates Clinical Trial For Actiseal Surgical Patch
Executive Summary
The Dutch company received the US FDA's breakthrough device designation in 2018 for the surgical patch.
You may also be interested in...
Polyganics Goes Shopping For Technology And Talent
The Netherlands-based biomaterials start-up intends to expand its platform's reach through strategic partnerships and tuck-in acquisitions.
Qiagen’s Ambitions: Standing Alone And Strengthening Infectious Disease Portfolio
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.
Angle Files De Novo Submission For Parsortix System In Breast Cancer
The system has the potential to be the first FDA-cleared device for harvesting intact cancer cells from a blood sample for subsequent analysis.